Conference Call Tuesday, May 11th,
9:00AM EDT
BOONTON, N.J., Apr 28, 2010 (BUSINESS WIRE) --UnigeneLaboratories, Inc. (OTCBB: UGNE)(http://www.unigene.com)
will release financial results for the quarter ended March 31, 2010,
after the market closes on Monday, May 10, 2010. The Company will host a
conference call the following morning, Tuesday, May 11, 2010, at 9:00 AM
EDT, to discuss its 2010 first quarter financial results and to provide
a Company update from our Chairman Richard Levy.
Unigene invites all those interested in hearing management's discussion
to join the call by dialing 877-407-8035 for participants in the United
States and 201-689-8035 for international participants. A replay will be
available for seven days after the call and can be accessed by dialing
877-660-6853 for participants in the United States and 201-612-7415 for
international participants. When prompted, enter account number 286 and
conference ID#350056. The conference call may also be accessed via the
Web at http://www.unigene.com;
a link will be provided for listeners to join the call.
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on
the oral and nasal delivery of large-market peptide drugs. Due to the
size of the worldwide osteoporosis market, Unigene is targeting its
initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith
Laboratories, worldwide rights for its oral PTH technology to
GlaxoSmithKline, worldwide rights for its calcitonin manufacturing
technology to Novartis and worldwide rights (except for China) for its
oral calcitonin program to Tarsa Therapeutics, Inc. Unigene's patented
oral delivery technology has successfully delivered, in preclinical
and/or clinical trials, various peptides including calcitonin and PTH
analogs. Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 265-1100 or visit www.unigene.com.
For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform
Act of 1995: This press release contains forward-looking statements as
defined in Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are based upon Unigene Laboratories, Inc.'s
management's current expectations, estimates, beliefs, assumptions, and
projections about Unigene's business and industry. Words such as
"anticipates," "expects," "intends," "plans," "predicts," "believes,"
"seeks," "estimates," "may," "will," "should," "would," "potential,"
"continue," and variations of these words (or negatives of these words)
or similar expressions, are intended to identify forward-looking
statements. In addition, any statements that refer to expectations,
projections, or other characterizations of future events or
circumstances, including any underlying assumptions, are forward-looking
statements. These forward-looking statements are not guarantees of
future performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Therefore, our actual results
could differ materially and adversely from those expressed in any
forward-looking statements as a result of various risk factors. These
risks and uncertainties include the risks associated with the effect of
changing economic conditions, trends in the products markets, variations
in Unigene's cash flow, market acceptance risks, technical development
risks and other risk factors detailed in Unigene's Securities and
Exchange Commission filings.
SOURCE: Unigene Laboratories, Inc.
The Investor Relations Group
Investors:
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210
|
